RxDoctor Payments Data

Rolf Poser, MD

Cardiovascular Disease · Columbus, WINPI 1013910645

Payments from drug & device makers

$5,136in general payments, 2019–2025

Across 354 payments — averaging $14.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$692
  • Johnson & Johnson$692
  • AstraZeneca$531
  • Novo Nordisk$457
  • Lilly USA, LLC$426
  • Boehringer Ingelheim$326
  • plus $2K from 30 others

What the payments were for

  • Food & beverage$5,10499%
  • Education$311%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,136 in reported general payments places this provider in the 70th percentile of 322 cardiovascular disease providers in Wisconsin.

See all cardiovascular disease providers in Wisconsin

Medicare billing

Part B allowed, 2024
$188,244
Medicare patients
688
Services billed
5,275

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban239$228,367
XareltoRivaroxaban88$107,615
FarxigaDapagliflozin Propanediol34$29,387
OzempicSemaglutide25$23,769
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$16,726
Tresiba Flextouch U-100Insulin Degludec24$12,874
CreonLipase/Protease/Amylase12$11,722
CelebrexCelecoxib11$9,602
NexletolBempedoic Acid16$7,758
Metoprolol Succinate312$5,142
Potassium Chloride205$4,146
Lantus SolostarInsulin Glargine,hum.Rec.Anlog46$3,804
Ezetimibe130$3,775
Atorvastatin Calcium335$3,618
Levothyroxine Sodium282$3,517

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Celebrex$692$237,969250 claims
Johnson & JohnsonXarelto$692$107,61588 claims
AstraZenecaFarxiga, Crestor$531$32,68346 claims
Novo NordiskOzempic$457$23,76925 claims
GSKTrelegy Ellipta$126$16,72623 claims
AbbVieCreon, Synthroid$317$13,08750 claims
Esperion Therapeutics, Inc.Nexletol$13$7,75816 claims
Kowa Pharmaceuticals America, Inc.Bystolic$11$2,31613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 322 cardiovascular disease providers in Wisconsin.

Other cardiovascular disease in Columbus

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →